Elicio Therapeutics, Inc. Proceeds from Notes Payable
Elicio Therapeutics, Inc. (ELTX) reported Proceeds from Notes Payable of $0 for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromNotesPayable · last filed 2026-08-13
- Elicio Therapeutics, Inc. proceeds from notes payable for the quarter ending 2025-12-31 was $0.00.
- Elicio Therapeutics, Inc. proceeds from notes payable for the quarter ending 2025-09-30 was $0.00.
- Elicio Therapeutics, Inc. proceeds from notes payable for the quarter ending 2025-06-30 was $9.52M.
- Elicio Therapeutics, Inc. proceeds from notes payable for the quarter ending 2025-03-31 was $343.00K.
- Elicio Therapeutics, Inc. proceeds from notes payable for fiscal 2025 was $9.87M.
- Elicio Therapeutics, Inc. proceeds from notes payable for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Elicio Therapeutics, Inc. proceeds from notes payable for fiscal 2023 was $10.00M.
- Elicio Therapeutics, Inc. proceeds from notes payable for fiscal 2022 was $0.00.
| Period end | Proceeds from Notes Payable 3 month | Proceeds from Notes Payable 6 month | Proceeds from Notes Payable 9 month | Proceeds from Notes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $9.52M derived: sum of 3 quarters · filed 2026-08-13 | $9.87M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $9.52M derived: sum of 2 quarters · filed 2026-08-13 | $9.87M 10-Q · filed 2025-11-13 | $9.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $9.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $9.87M 10-Q · filed 2026-08-13 | $9.87M derived: sum of 3 quarters · filed 2026-08-13 | $9.87M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $343.00K 10-Q · filed 2025-05-13 | $343.00K derived: sum of 2 quarters · filed 2026-03-12 | $343.00K derived: sum of 3 quarters · filed 2026-03-12 | $343.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-03-12 | $0.00 10-K · filed 2026-03-12 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2025-11-13 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $0.00 10-Q · filed 2025-08-07 | $0.00 derived: sum of 3 quarters · filed 2025-08-07 | $0.00 derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-13 | $0.00 derived: sum of 2 quarters · filed 2025-05-13 | $0.00 derived: sum of 3 quarters · filed 2025-05-13 | $0.00 derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $0.00 derived: sum of 2 quarters · filed 2025-03-31 | $0.00 derived: sum of 3 quarters · filed 2025-03-31 | $10.00M 10-K · filed 2025-03-31 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $0.00 derived: sum of 2 quarters · filed 2024-11-13 | $10.00M 10-Q · filed 2024-11-13 | $10.00M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $10.00M 10-Q · filed 2024-08-13 | $10.00M derived: sum of 3 quarters · filed 2024-08-13 | $10.00M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $10.00M 10-Q · filed 2024-05-15 | $10.00M derived: sum of 2 quarters · filed 2024-05-15 | $10.00M derived: sum of 3 quarters · filed 2024-05-15 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | $0.00 derived: sum of 2 quarters · filed 2024-03-29 | $0.00 10-K · filed 2024-03-29 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $0.00 10-Q · filed 2023-11-13 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $0.00 derived: sum of 3 quarters · filed 2022-03-30 | $0.00 10-K · filed 2022-03-30 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $0.00 derived: sum of 2 quarters · filed 2021-11-12 | $0.00 10-Q · filed 2021-11-12 | $0.00 derived: sum of 4 quarters · filed 2022-03-30 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $0.00 10-Q · filed 2021-08-12 | $0.00 derived: sum of 3 quarters · filed 2022-03-30 | $17.29M derived: sum of 4 quarters · filed 2022-03-30 |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-17 | $0.00 derived: sum of 2 quarters · filed 2022-03-30 | $17.29M derived: sum of 3 quarters · filed 2022-03-30 | $28.17M derived: sum of 4 quarters · filed 2022-03-30 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-30 | $17.29M derived: sum of 2 quarters · filed 2022-03-30 | $28.17M derived: sum of 3 quarters · filed 2022-03-30 | $31.22M 10-K · filed 2022-03-30 |
| 2020-09-30 | $17.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $28.17M derived: sum of 2 quarters · filed 2021-11-12 | $31.22M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $10.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $13.94M 10-Q · filed 2021-08-12 | ||
| 2020-03-31 | $3.05M 10-Q · filed 2021-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |